TSS
IDXX icon

Thomas Story & Son’s Idexx Laboratories IDXX Stock Holding History

Thomas Story & Son’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-36,700
Closed -$2.23M – 60
2014
Q1 		$2.23M Hold
36,700
– – 1.21% 29
2013
Q4 		$1.95M Sell
36,700
-1,000
-3% -$52.6K 1.07% 30
2013
Q3 		$1.88M Hold
37,700
– – 1.16% 28
2013
Q2 		$1.69M Buy
+37,700
New +$1.65M 1.06% 30

Other funds holding IDXX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Thomas Story & Son's IDXX Position: Q2 2014 in Review

Thomas Story & Son sold out of Idexx Laboratories (IDXX) in Q2 2014, closing a stake of 36,700 shares — an estimated $2.23M sold.

Thomas Story & Son first reported a position in IDXX in Q2 2013 and held it in 4 quarters. The position peaked at $2.23M in Q1 2014. 306 funds tracked by Wall St. Rank hold IDXX as of Q2 2014.

  • Thomas Story & Son reported no remaining Idexx Laboratories position as of Q2 2014 after selling out during the quarter.
  • Thomas Story & Son sold 36,700 Idexx Laboratories shares in Q2 2014, an estimated $2.23M.
  • Thomas Story & Son first reported a position in Idexx Laboratories in Q2 2013 and held it in 4 quarters.
  • Thomas Story & Son's Idexx Laboratories position peaked at $2.23M in Q1 2014.
  • 306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2014.

Based on Thomas Story & Son's 13F filing for Q2 2014, filed 1 Aug 2014.